Christopher Carpenter
Infectious Disease · Royal Oak, MINPI 1003875600
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,330 of the $27,436 with a category attached, or 96.0%. 3 manufacturers reported payments, led by GSK at 38.6% of the total. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $2110.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Shionogi Inc$9K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
Across 60 payments — averaging $16,348 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$929K
- Dompe Farmaceutici S.p.a.$52K
What the payments were for
- Consulting fees$26,33096%
- Travel & lodging$9503%
- Food & beverage$1561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $10,580 |
| Shionogi Inc | 10 | $9,106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $7,750 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,436 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 65 | $309,658 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 38 | $136,626 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 23 | $104,135 |
| TivicayDolutegravir Sodium | 33 | $76,985 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $49,491 |
| IsentressRaltegravir Potassium | 23 | $48,635 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 13 | $33,134 |
| Etravirine | 12 | $12,751 |
| Darunavir | 17 | $11,169 |
| Ritonavir | 16 | $5,249 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Royal Oak
- Matthew SimsRoyal Oak$4K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.